Cart
sales@molnova.com
Formoterol
CAS No. 73573-87-2
Formoterol ( —— )
Catalog No. M15814 CAS No. 73573-87-2
Formoterol is a novel highly β2-selective adrenergic agonist and holds promise as a β2-agonist that could impart selective beneficial metabolic effects.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 66 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 192 | In Stock |
|
| 50MG | 339 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFormoterol
-
NoteResearch use only, not for human use.
-
Brief DescriptionFormoterol is a novel highly β2-selective adrenergic agonist and holds promise as a β2-agonist that could impart selective beneficial metabolic effects.
-
DescriptionFormoterol is a novel highly β2-selective adrenergic agonist and holds promise as a β2-agonist that could impart selective beneficial metabolic effects.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAdrenergic Receptor
-
Recptorβ2-adrenergic receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number73573-87-2
-
Formula Weight344.40
-
Molecular FormulaC19H24N2O4
-
Purity>98%(HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESC[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kobayashi Y, et al. Pulm Pharmacol Ther. 2012 Jun;25(3):201-7.
molnova catalog
related products
-
Tizanidine hydrochlo...
Tizanidine hydrochloride is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.
-
Formoterol Hemifumar...
Formoterol Hemifumarate is a potent, selective and long-actingβ2-adrenoceptor agonist used in the management of asthma and chronic obstructive pulmonary disease(COPD).
-
Esmolol hydrochlorid...
Esmolol Hydrochloride is a beta adrenergic receptor blocker.
